Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;1865(2):228-36.
doi: 10.1016/j.bbcan.2016.03.003. Epub 2016 Mar 8.

Necroptosis: an alternative cell death program defending against cancer

Dongshi Chen  1 , Jian Yu  2 , Lin Zhang  3
Affiliations
Review

Necroptosis: an alternative cell death program defending against cancer

Dongshi Chen et al. Biochim Biophys Acta. 2016 Apr.

Abstract

One of the hallmarks of cancer is resistance to programmed cell death, which maintains the survival of cells en route to oncogenic transformation and underlies therapeutic resistance. Recent studies demonstrate that programmed cell death is not confined to caspase-dependent apoptosis, but includes necroptosis, a form of necrotic death governed by Receptor-Interacting Protein 1 (RIP1), RIP3, and Mixed Lineage Kinase Domain-Like (MLKL) protein. Necroptosis serves as a critical cell-killing mechanism in response to severe stress and blocked apoptosis, and can be induced by inflammatory cytokines or chemotherapeutic drugs. Genetic or epigenetic alterations of necroptosis regulators such as RIP3 and cylindromatosis (CYLD), are frequently found in human tumors. Unlike apoptosis, necroptosis elicits a more robust immune response that may function as a defensive mechanism by eliminating tumor-causing mutations and viruses. Furthermore, several classes of anticancer agents currently under clinical development, such as SMAC and BH3 mimetics, can promote necroptosis in addition to apoptosis. A more complete understanding of the interplay among necroptosis, apoptosis, and other cell death modalities is critical for developing new therapeutic strategies to enhance killing of tumor cells.

Keywords: Cancer; MLKL; Necroptosis; RIP1; RIP3.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Morphological features of necroptosis and apoptosis in cancer cells
HT29 colon cancer cells treated with an anticancer drug for 48 hours were analyzed by transmission electron microscopy. The cell undergoing necroptosis shows plasma membrane rupture and permeabilization, compared to the intact plasma membrane with blebbing in the apoptotic cell (red arrowheads). The necroptotic cell exhibits cytoplasm swelling and vacuolization, which are absent in the apoptotic cell (green arrowheads). The necroptotic cell has swelled mitochondria, in contrast to those in the apoptotic cells (yellow arrowheads). The necroptotic cell also lacks condensed and fragmented nuclei seen in the apoptotic cell (blue arrowheads).
Figure 2
Figure 2. Necroptosis regulators and pathways
Upon TNF-α stimulation, the activated TNF receptor (TNFR) interacts with RIP1 and recruits cIAP1 and cIAP2 to form a plasma membrane associated complex, resulting in RIP1 polyubiquitination (Ubs). Inhibition of cIAPs (by SMAC or SMAC mimetics) leads to deubiquitination of RIP1 by CYLD and dissociation of RIP1. RIP1 then binds to FADD and procaspase-8 to form a complex, which activates caspase-8 (Casp-8) and leads to apoptosis induction. If caspase-8 activity is inhibited, RIP1 binds to RIP3 to form necrosome and promotes RIP3 auto-phosphorylation and subsequent activation, allowing RIP3 to recruit and phosphorylate MLKL. This results in oligomerization of MLKL, membrane insertion of MLKL oligomers, disruption of plasma and intracellular membrane integrity, and necroptotic death. Other necroptotic stimuli, including FASL, TRAIL, LPS, dsRNA (such as poly (I:C)) and interferon γ (IFNγ), can stimulate their respective receptors to activate RIP1 and/or RIP3 to promote necroptosis. Viral infection directly activates RIP3 through DAI. Anticancer agents and genotoxic stress can also induce RIP1/RIP3-dependent necroptosis. Several inhibitors of necroptosis have been developed, including the RIP1 inhibitor necrostatin-1 (Nec-1), the RIP3 inhibitors GSK843 and GSK872, and the MLKL inhibitor necrosulfonamide (NSA).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. - PubMed
    1. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, Lipton SA, Lu X, Madeo F, Malorni W, Mehlen P, Nunez G, Peter ME, Piacentini M, Rubinsztein DC, Shi Y, Simon HU, Vandenabeele P, White E, Yuan J, Zhivotovsky B, Melino G, Kroemer G. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107–120. - PMC - PubMed
    1. Vercammen D, Beyaert R, Denecker G, Goossens V, Van Loo G, Declercq W, Grooten J, Fiers W, Vandenabeele P. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med. 1998;187:1477–1485. - PMC - PubMed
    1. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nature immunology. 2000;1:489–495. - PubMed
    1. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nature chemical biology. 2005;1:112–119. - PubMed

Publication types

Substances